Associations of Genetic Polymorphism of Cancer Related Genes and Drug Metabolizing Enzymes with Variability in Breast Cancer Patients’ Responses to Therapeutic Intervention among Bangladeshi Females: Pharmacogenetic Relevance to Precision Medicine

According to GLOBOCAN, breast cancer is the fifth leading cause of morbidity in the world. Environmental and genetic factors play crucial roles in the development of breast cancer and the risk of developing breast cancer have been reported to be different among ethnicities and even among individuals. Ggenetic polymorphisms,presents persistent source of variation in individual’s response to drugs. Precision medicine for breast cancer is a personalized approach to diagnosis and treatment that considers a patient's genetic makeup, especially genetic polymorphisms, and tumor characteristics. The aim of this research is to comprehensively investigate the impact of various genetic polymorphisms in breast cancer related genes and drug metabolizing enzymes on the therapeutic response, drug toxicity, and survival outcomes among Bangladeshi breast cancer patients, with the ultimate goal to form the basis of precision medicine. The investigation will focus on identifying the genetic variants that are associated with breast cancer pathogenesis, therapeutic failure and drug toxicities. We plan to study polymorphisms in BRCA1, BRCA2, ER, PR, HER1 etc. and CYP2A6, CYP3A4, CYP1A2, CYP2B6, CYP4A11, CYP2C8, CYP2C9 etc. Our findings

will contribute to form the basis of personalized therapeutic strategies by developing dose-tailoring approaches based on patient genotypes. By understanding how genetic variations affect drug metabolism, treatments can be personalized, leading to higher efficacy, reduced side effects and extended survival of a significant part of Bangladeshi population. Completion of this project will increase the research capability of the entity for graduate, postgraduate students and faculties.

• Research Project